Neurolixis
New treatments for central nervous system disorders
New treatments for central nervous system disorders
Neurolixis is a biopharmaceutical company headquartered in the United States and founded in 2011. The company is dedicated to developing innovative drugs targeting a variety of central nervous system diseases such as movement disorders, autism spectrum disorders, depression, and pain. Neurolixis aims to provide new treatments in these areas. In July 2013, the company secured a $15.00K Seed Round investment, indicating initial investor confidence in its innovative developments and potential to address unmet medical needs in the field of health care.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $15.00K | - | 18 Jul 2013 |
No recent news or press coverage available for Neurolixis.
We care about your data, and we'd love to use cookies make your experience better.
